Develops, manufactures and sells branded and generic pharmaceutical formulations across India, North America, Europe and emerging markets. FY26 consolidated revenue of Rs 16,982.51 crore grew 27.5% YoY, driven heavily by North America jumping 136.6% YoY on recognition of an AbbVie licensing deal for ISB 2001 worth USD 700 million upfront and potential USD 1.925 billion total. India revenue fell 17% YoY to Rs 37,237 million, while Europe and Emerging Markets posted 21.4% and 13.7% growth respectively. The portfolio spans branded speciality products such as RYALTRIS nasal spray and WINLEVI, plus a US generics pipeline that launched 13 products in FY26 and 9 in Q1 FY27, including the first generic FloVent HFA with 180-day exclusivity. Manufacturing includes a Goa facility inspected by the US FDA in June 2026 with six procedural observations and a Monroe facility classified VAI after inspection. R&D spend in Q1 FY27 was Rs 2,494 million. Cost structure is led by other operating expenses at 24.1% of revenue, employee costs at 21.1% and materials at 17.4%, with capex at 8.0% of revenue. AR · MarketPing reader · 2026-08-03
Revenue streams, as the annual report describes them. North America, India formulations, Europe, Emerging Markets, Licensing and out-licensing income. Global branded and generic pharmaceuticals with R&D-driven licensing, injectables and speciality launches.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 12,305 | 12,990 | 11,813 | 13,322 | 16,983 |
| EBITDA (ex other income) | 2,059 | 1,513 | 294 | 1,979 | 2,306 |
| margin % | 16.7 | 11.6 | 2.5 | 14.9 | 13.6 |
| Owners' profit | 942 | 0 | (1,502) | 1,047 | 0 |
| EPS, as reported (₹) | 33.37 | 10.53 | (53.22) | 37.11 | 48.26 |
| ROE % · ROCE % | 10.5 · 14.0 | 3.8 · 8.5 | (18.3) · 6.5 | 11.8 · 15.9 | 13.0 · 16.2 |
| Debt / equity (x) | 0.39 | 0.44 | 0.13 | 0.25 | 0.00 |
| Cash from operations | 1,109 | 625 | (265) | (828) | 3,445 |
| Capex | (790) | (608) | (898) | (750) | (1,358) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3,434 | 3,388 | 3,256 | 3,264 | 6,047 | 3,901 | 3,771 | 4,018 |
| Profit before tax | 473 | 456 | 8 | 96 | 967 | 534 | 388 | 643 |
| Net profit | 354 | 348 | 4 | 47 | 610 | 403 | 301 | 483 |
| EPS (₹) | 12.55 | 12.33 | 0.16 | 1.66 | 21.63 | 14.29 | 10.68 | 17.11 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 11 Sept 2026 · Glenmark 48th AGM: All resolutions passed, dividend of Rs 2.50/share declared | board shareholder meetings | medium | — | — |
| 11 Sept 2026 · Glenmark launches RYALTRIS allergy nasal spray in Brazil | compliance | medium | — | — |
| 11 Sept 2026 · Glenmark Pharma bank loan rating upgraded to IND AA+ with Stable outlook | credit debt | medium | — | — |
| 21 Aug 2026 · Glenmark's US arm launches Calcium Gluconate Injection in US market | business updates | medium | — | — |
| 20 Aug 2026 · Glenmark gets U.S. FDA approval for Fluticasone Nasal Spray | business updates | high | — | — |
| 13 Aug 2026 · Glenmark sends AGM notice and annual report link to shareholders without registered email | compliance | minimal | — | — |
| 13 Aug 2026 · Glenmark Pharma files BRSR for FY 2025-26 | compliance | minimal | — | — |
| 13 Aug 2026 · Notice of 48th AGM and FY26 Integrated Annual Report | board shareholder meetings | low | — | — |
| 13 Aug 2026 · 48th AGM on Sept 11, 2026; Dividend of INR 2.50 per share declared | board shareholder meetings | low | — | — |
| 13 Aug 2026 · Glenmark 48th AGM on Sept 11, 2026 via VC; dividend of INR 2.50/share | board shareholder meetings | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| 18.0 |
| 12.4 |
| 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 38.0 | 28.9 | 108 of 169 | 36% |
| P/B | 6.5 | 3.3 | 132 of 163 | 19% |
| ROCE | 14.7 | 10.8 | 68 of 183 | 63% |
| ROE | 13.0 | 10.4 | 60 of 171 | 65% |
| Debt / Equity | 0.0 | 0.1 | 6 of 171 | 77% |
| EBITDA margin | 21.7 | 17.5 | 68 of 165 | 59% |
| Revenue growth | 23.1 | 16.3 | 62 of 161 | 62% |
| Profit growth | 927.9 | 30.9 | 8 of 158 | 96% |
| Market cap | 68270 | 839 | 11 of 182 | 95% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
